Roche snaps up U.S. biotech Promedior for up to $1.4 billion for idiopathic pulmonary fibrosis drug

LONDON, 15 Nov (APM) - Roche is buying privately-owned Promedior for up to $1.4 billion, it was announced on Friday.
Its leading drug candidate against lung disease idiopathic pulmonary fibrosis is set to begin late-stage trials, Promedior said.
The deal includes a payment of $390 million, plus the potential for $1 billion more if conditions are met.
The U.S. biotech said its lead candidate, PRM-151, has demonstrated in Phase II that it is is the first molecule to show significant lung function improvements on top of current therapies in IPF.
"PRM-151 has also shown promising early clinical trial data in myelofibrosis (MF) and its anti-fibrotic mechanism has therapeutic potential in other fibrotic diseases."
Roche already has an IDF drug, Esbriet (pirfenidone), with sales in 2018 of just over $1 billion.
The Swiss pharma is also in the process of trying to buy gene therapy specialist Spark Therapeutics for $4.3 billion, but the deal is being stalled by competition investigations. (APMHE 64904)



Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations

Events coverage with a unique focus on Market Access & sustainability of healthcare systems

6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris

Ask for a Free trial and get access to the latest stories

Our coverage includes:
  • Health Care
  • Market Access
  • HTA – policies & practices
  • European medicine regulations
  • Drug safety issues
  • Pricing & Reimbursement
  • International medicines agencies

If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.


an initial 10 day temporary access of APM Health Europe.